Pelotonia Fellowship Symposium

The sharing of ideas and the development of collaborations are two cornerstones of the Pelotonia Fellowship Program. To this end, a yearly scientific symposium brings together awardees, their mentors, world class scientists and leaders from the community.

2019 Symposium

The 2019 Pelotonia Fellowship Symposium will once again feature world-renowned scientists and the work of undergraduate, graduate and postdoctoral fellows whose work is supported by funds raised through Pelotonia. The symposium took place on October 28, 2019 at The Fawcett Center.

2019 Speakers

Raymond DuBoisRaymond N. DuBois, MD, PhD
Dean, College of Medicine
Professor, Departments of Biochemistry and Medicine
Medical University of South Carolina
TOPIC: Inflammation and Inflammatory Mediators as Potential Targets for Cancer Prevention and/or Interception

Raymond N. DuBois, MD, PhD, was named Dean of the College of Medicine at the Medical University of South Carolina in March of 2016. Prior to this position, Dr. DuBois served as xecutive director of the Biodesign Institute in Arizona (ASU) and as the Dalton Professor of Chemistry and Biochemistry with a joint appointment as Professor of Medicine in the Mayo College of Medicine. From 2007 to 2012, he served as provost and executive vice president at the University of Texas MD Anderson Cancer Center in Houston and held the Ellen Knisely Distinguished Chair in Colon Cancer Research. During his tenure at Vanderbilt University Medical Center (1991-2007), he served as director of the Division of Gastroenterology, Hepatology & Nutrition as well as director of the Vanderbilt-Ingram Cancer Center. He also was selected to hold three successive endowed chairs at Vanderbilt, including the Mina Cobb Wallace Chair, the Hortense B. Ingram Chair and the Benjamin F. Byrd Chair. In 2015 he was honored at Vanderbilt by inclusion as an honorary member in the Tinsley Harrison Society at the Vanderbilt University School of Medicine.

Dr. DuBois is an internationally renowned expert and is known for his work elucidating the role of inflammation and inflammatory mediators in the progression of cancer. His laboratory examines the molecular mechanisms by which inflammatory mediators affect epithelial biology, the tumor microenvironment and cancerization. In the 1990s, DuBois and colleagues made the landmark discovery that colorectal tumors contained high levels of a key enzyme (COX-2) that regulates prostaglandin production. COX-2 catalyzes a key step in the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2). This work and other studies led to a better understanding of the role of anti-inflammatory agents, like aspirin, in reducing cancer risk, which led to clinical trials showing how drugs that inhibit this pathway could prevent or intercept the process of cancer development. More recent studies have revealed that PGE2 regulates the immune status of the tumor microenvironment and inhibitors of PGE2 signaling block tumor metastasis and cancer progression.

Dr. DuBois is a Fellow of the American Association for the Advancement of Science (AAAS) and the American Association for Cancer Research (AACR). In 2019, he was awarded the AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research. Other major awards for his cancer research include the Richard and Hinda Rosenthal Research Award, the Dorothy P. Landon-AACR Cancer Prize and the Anthony Dipple Carcinogenesis Award given by Oxford University Press. He is a past president of AACR, the Southern Society for Clinical Investigation and the International Society for Gastrointestinal Cancer. In 2018, he was named to the steering committee for the AACR Academy and selected as a vice chair for the Stand Up to Cancer (SU2C) Scientific Advisory Board. He is also a member of the American Clinical and Climatological Association, the Royal College of Physicians (by distinction), the Association of American Physicians and the American Society for Clinical Investigation. Dr. DuBois also serves as an editor-in-chief for Cancer Prevention Research, published by AACR.

During his career as a physician-scientist, DuBois has published over 160 peer reviewed research articles, more than 60 review articles, 25 book chapters and three books. His work has been cited over 59,000 times according to Google Scholar. He is also a co-inventor of a method to identify and target cellular genes needed for viral growth as well as cellular genes that function as tumor suppressors in mammals.

DuBois earned a bachelor’s degree (Biochemistry with honors) from Texas A&M University and a doctoral degree (Biochemistry) from The University of Texas Southwestern Medical Center in Dallas. He obtained a medical degree from The University of Texas School of Medicine in San Antonio, followed by completion of an Osler Medicine internship/residency and a gastroenterology fellowship at Johns Hopkins Hospital in Baltimore. In 2007, he was honored at Hopkins by being inducted into the Johns Hopkins University Society of Scholars.

Ann-Kathrin Eisfeld, MD, was born and raised close to Hamburg, Germany, where she attended medical school at the University of Leipzig when she was 19 years old. She was already fascinated by hematology during my first year of medical school, especially acute myeloid leukemia. Under the mentorship of Dietger Niederwieser and Haifa Kathrin Al-Ali, she started researching the effects of iron overload in patients undergoing stem cell transplantation, including the effects of HFE genotype changes and Hepcidin expression. Her research resulted in two first authorship publications, four oral presentations at international meetings and the initiation of a phase III clinical trial (Novartis DE02), in which she served as co-principal investigator. After graduation, she was offered the opportunity to start residency training with a focus on stem cell transplantation, including work on the PBSCT unit and also the outpatient clinic. Thus, she began a residency/fellowship in the Department of Hematology and Oncology at the University of Leipzig.

With all the novel targeted agents and molecular markers being presented at the international meetings, she wanted to understand more about the molecular background in AML and to learn more about both basic and translational research. After two and a half years of clinical training, she was given the unique opportunity to start a postdoctoral fellowship under the mentorship of not  only one but two of the most distinguished and world-renowned experts in the fields of AML and cancer genetics: Clara D. Bloomfield and Albert de la Chapelle at The Ohio State University in Columbus, Ohio. Under their joint supervision, she was trained in translational research (with a focus on prognostically significant molecular markers in AML) as well as basic molecular biology and cancer genetics. Her discoveries include the prognostic significance and underlying signaling pathway of miR-3151, an intronic microRNA which is located in the genomic locus of the BAALC gene, and also the identification and molecular characterization of novel isoforms of the NRAS gene. In the past two years, she expanded her research to the targeted next-generation sequencing analysis of a large cohort of AML patients. Some of the corresponding manuscripts are currently in revision, under review or in advanced preparation.

During her postdoctoral fellowship, she especially enjoyed mentoring gifted undergraduate and high school students. This resulted in separate first-author papers for three of her students where she is the last author, including a publication in Cancer Discovery, which was accepted in June 2016. This work describes the discovery of miR-3662 as a novel player in the prominent hematopoietic quantitative trait locus on chromosome 6q23.3, which regulates erythroid differentiation via the NF-KB pathway. She was awarded the Pelotonia Postdoctoral Fellowship in 2011, the Alliance Young Investigator Award in 2012 and was accepted as a 2013 TRTH trainee, which is a rigorous course in translational research for 20 selected trainees world-wide. Also in 2014, together with Drs. Carson and de la Chapelle, she received a Pelotonia IDEA Grant, which supported their research on miR-3151 and NRAS. She successfully took the USMLEs and applied for residency training in physician scientist training programs at Ohio State.

Daniel L. Kiss, PhD, is an assistant professor of Cardiovascular Sciences at Houston Methodist Research Institute. Dr. Kiss completed both a Bachelor’s and a Master’s degree in Biology at Cleveland State University. He began his interest in RNA molecular biology as a graduate student at Case Western Reserve University. After earning his PhD at Case Western, he continued his RNA molecular biology training when he came to Ohio State as a Pelotonia postdoctoral fellow in Dr. Daniel Schoenberg’s lab in 2011. He stayed at Ohio State until he started his own lab at the Houston Methodist Research Institute at the start of 2018. Dr. Kiss’s lab continues his years-long focus on RNA biology and disease. In addition to his work at Houston Methodist Research Institute, he also has affiliations with the Houston Methodist Cancer Center and Weill Cornell Medical College.

Christopher Koivisto, PhD, is a veterinarian with advanced training in pathology and comparative medicine. He first became interested in cancer research working as a technician, performing audits of animal studies used for toxicity and carcinogenicity testing. That experience motivated him to pursue veterinary education and subsequent residency and graduate training. He earned his DVM from North Carolina State University and completed a residency/PhD program at The Ohio State University. Dr. Koivisto’s research interests employ genomics and mouse models to dissect the pathogenesis of cancer initiation and progression. His primary efforts focus on uterine cancer, where he identifies genomic alterations present in human tumors and models them in mice as an effort to identify novel approaches for prevention or treatment of cancer. In addition, Dr. Koivisto works with multiple Hollings’ investigators to interpret alterations that occur within their animal models and help design further experiments necessary for building upon and validating initial observations. This multidisciplinary approach is essential for translational science, where scientific discoveries are turned into clinical applications.

Nancy Engelmann Moran, PhD, is an assistant professor at the USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine. She earned her B.S. from the University of Illinois-Urbana/Champaign in Molecular and Cellular Biology (2005), her doctoral degree from University of Illinois in Nutritional Sciences (2010) and completed her postdoctoral training at The Ohio State University in the Comprehensive Cancer Center (2016) with medical oncologist Steven K. Clinton, MD, PhD. She is an assistant professor of Pediatric Nutrition at the Baylor College of Medicine and USDA/Agricultural Research Service’s Children’s Nutrition Research Center. Her translational research principally addresses the absorption and metabolism of dietary bioactive compounds in humans and model systems for the benefits of cancer prevention and infant and maternal health. Her research is supported by the NIH, USDA and Texas Children’s Hospital. She is an active member of the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine. She served as the Chair of the Ohio State Postdoctoral Association (2015-2016), the Chair of the American Society for Nutrition’s Carotenoid and Vitamin A Research Interactive Group (2018-2019) and currently leads the Postdoctoral Training Program Seminar Series at the Children’s Nutrition Research Center. While at Ohio State, she received the 2016 Postdoc of the Year Award and Postdoctoral Research Award from the American Society for Nutrition. Dr. Moran recently received awards for the top poster in Cancer Prevention and Population Sciences for the Duncan Cancer Center Symposium and Top Reviewer for the journal Current Developments in Nutrition.

Parvathi Ranganathan, PhD, is an assistant professor at The Ohio State University, College of Medicine. She obtained her PhD from the University of Arizona in 2014. Her passion to pursue a career in immunology is sparked by her fascination of T lymphocytes, a diverse subset of cells that display multifunctional properties and one of the most powerful weapons in the arsenal of the human immune system. This led her to University of Arizona for her PhD training focused on investigating the role of autoantibodies to the T cell receptor in autoimmune diseases such as rheumatoid arthritis. During her post-doctoral training at Ohio State under mentor Ramiro Garzon, her research efforts were focused on investigating the immunomodulatory role of microRNAs in “allo-immune” disease-aGVHD (for which she received a Pelotonia postdoctoral fellowship) as well as developing novel therapeutic strategies in acute myeloid leukemia (which earned her a Leukemia and Lymphoma Society Special Fellow Award). Her past research experiences have laid the foundation for building her independent research laboratory that utilizes a combination of in vitro and in vivo preclinical mouse models of disease to investigate the function of diverse T cell subsets (T helper, T cytotoxic, T regulatory) post-transplant. The research goal of her laboratory is to investigate mechanisms regulating T cell responses post allogeneic hematopoietic cell transplant, with the objective of developing selective therapies that abrogate acute graft-versus-host disease (aGVHD) while maintaining T cell responses needed to preserve the beneficial graft-versus leukemia (GVL) effect. The specific foci of investigation of her research laboratory are: 1) The role of epigenetic modifiers (BRD4 and PRMT5) on T cell function and aGVHD; 2) The role of microRNAs in modulating T cell responses and engraftment post-transplant; 3) novel biomarker discovery and validation in aGVHD; and 4) translation of preclinical (biomarker and therapeutic) discoveries to the clinic to improve patient outcomes post-transplant.

Carlee Schaefer, PhD, is currently a postdoc researcher at Beaumont Hospital near Detroit, Michigan. She studies joint conditions and is working to develop autologous stem cell therapy to treat and prevent post traumatic osteoarthritis. Dr. Schaefer is originally from Dayton, Ohio. She received her Bachelors in Molecular Genetics from The Ohio State University in 2012 and her PhD from Ohio State in 2018 from the BSGP program. Her passion for research started as an undergraduate working in Dr. Debbie Parris’s lab studying herpes simplex virus and specifically how viral proteins interacted with host DNA replication machinery. In graduate school, she joined Scott Harper’s lab at Nationwide Children’s Hospital, where she developed animal models and helped develop gene therapy strategies to treat muscular dystrophy. After graduating, she worked as a clinical research coordinator with Kevin Flanigan’s group at Nationwide to learn more about clinical trial operations and experience more patient interaction.

Gina Sizemore, PhD, is an assistant professor in the Department of Radiation Oncology at The Ohio State University School of Medicine and a member of the Cancer Biology Program at the OSUCCC – James. Dr. Sizemore earned her B.A. in Biology at Washington and Jefferson College in 2003 before spending two years as a research assistant for Dr. Dennis Slamon at the University of California, Los Angeles. She then matriculated to Case Western Reserve University in 2005, where she earned her PhD in Pharmacology in 2011 under the guidance of Dr. Ruth Keri. After serving as a postdoctoral scholar there for a little over a year, Dr. Sizemore moved to Ohio State to gain expertise in the tumor microenvironment (TME) in the lab of Dr. Michael Ostrowski. From 2013-17, she was both a Pelotonia and Department of Defense Breast Cancer Research Program postdoctoral fellow. She then transitioned to faculty in the Department of Radiation Oncology in 2017.

Dr. Sizemore has been awarded numerous awards and fellowships over her career, including a Doctoral Excellence Award in Pharmacology at the Case Western Reserve University School of Medicine, a METAvivor Young Investigator Award and the Herbert and Maxine Block Lectureship Junior Faculty Award. She has authored or co-authored articles in prestigious journals as Nature Communications, Genes and Development, Molecular Cancer Research, Oncogene and the Journal of Biological Chemistry.

Dr. Sizemore’s research integrates in vitro cell line and in vivo mouse modeling of the breast metastatic TME to provide mechanistic insight breast cancer progression. Her lab’s current work aims to elucidate whether platelet-derived growth factor receptor-beta (PDGFRß) signaling is a promising pathway for diagnostic and/or therapeutic purposes for metastatic breast cancer patients. She is principal investigator for a K22 Transition Career Development Award from the National Cancer Institute for a study titled “PDGFR Beta Signaling in the Tumor Microenvironment of Metastatic Breast Cancer” that is utilizing a novel ˆmouse model to provide insight into how the brain metastatic TME contributes to breast cancer metastasis and how the TME within the brain can be targeted therapeutically to improve patient outcomes.

Salene M. W. Jones, PhD, is a psychologist whose research focuses on quality of life and anxiety. She obtained her bachelor degree in Psychology at University of Washington in 2003 followed by a master and a PhD, in 2019 and 2013 respectively, at The Ohio State University. She then conducted a postdoctoral fellowship at the Women's Health and Aging, Kaiser Permanente Washington Health Research Institute. She is particularly interested in psychometrics, which is the development of valid and reliable questionnaires for patient-reported outcomes to assess pain, depression, anxiety and other facets of quality of life. Dr. Jones also examines the association of financial worry and anxiety with outcomes in people with cancer and the effects of financial worry and anxiety on health behaviors. Her current research includes studies of the relationship of health anxiety and fear of cancer to health care use and cancer prevention.



Previous Invited External Speakers

2018


Nancy Ratner, PhD
Beatrice C. Lampkin Endowed Chair in Cancer Biology
Professor, Department of Pediatrics
Cincinnati Children’s Hospital, University of Cincinnati
Program Leader for Cancer Biology/Neural Tumors Program, Cancer and Blood Disorders Institute
TOPIC: Ras-GTP and Purinergic Signaling in Peripheral Nerve Tumors: Toward Therapy for Neurofibromatosis Type 1

David Tuveson, MD, PhD
Director, Cold Spring Harbor Laboratory Cancer Center
Chief Scientist, Lustgarten Foundation Pancreatic Cancer Research
Roy J. Zuckerberg Professor of Cancer Research  
TOPIC: Pancreatic Cancer Biology and Medicine

Joann B. Sweasy, PhD
The Ensign Professor of Therapeutic Radiology
Associate Director for Basic Science, Yale Comprehensive Cancer Center
Professor and Vice Chair, Dept. of Therapeutic Radiology
Yale University School of Medicine
TOPIC: DNA Repair and Lupus

2017


Virginia Araxie Zakian, PhD
Harry C. Wiess Professor in Life Sciences
Dept. of Molecular Biology
Princeton University
TOPIC: Unanticipated Mechanisms for Telomerase Regulation

Joan Conaway, PhD
Helen Nelson Distinguished Chair
Professor, Dept. of Biochemistry & Molecular Biology
The University of Kansas School of Medicine Stowers Institute for Medical Research
TOPIC: Roles of the Mediator Complex in RNA Polymerase II Transcription

Nikhil Wagle, MD
Assistant Professor of Medicine, Harvard Medical School
Deputy Director, Center for Cancer Precision Medicine Associate Member, Broad Institute
Dana Farber Cancer Institute
TOPIC: Translational Genomics and Precision Medicine in Metastatic Breast Cancer

2016


Shelly Berger, PhD Daniel S. Och University Professor
Director, Epigenetics Programs
University of Pennsylvania
TOPIC: Epigenetics Dysregulation in Senescence, Aging and Cancer

Valerie Weaver, PhD
Professor & Director, Center for Bioengineering and Tissue Regeneration
Director, Center for Human Immunology and Immunotherapy Programs
Co-Director Bay Area Center for Physical Sciences and Oncology
University of California, San Francisco
TOPIC: Forcing Form and Function

2015


Frank McCormick, PhD, FRS, DSc (Hon)
Professor Emeritus, UCSF Helen Diller Family Comprehensive Cancer Center
David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research
TOPIC: New Approaches to Targeting K-Ras

Brenda Schulman, PhD
Investigator, Howard Hughes Medical Institute
Joseph Simone Chair in Basic Research
St. Jude Children's Research Hospital
TOPIC: Twists and Turns in Ubiquitin Transfer Cascades

Philip Tsichlis, MD
Jane F Desforges Professor of Medicine
Tufts University

2014


Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center
TOPIC
: PI3K Pathway in Breast Cancer: Role in Tumor Progression and as a Therapeutic Target 

Guillermina (Gigi) Lozano, PhD
University of Texas MD Anderson Cancer Center
TOPIC
: Dissecting the p53 Pathway in vivo

David Beach, PhD, FRS
Blizard Institute
TOPIC
: The Cell Cycle and Cancer: Back to the Future

2013


Jon Aster, MD, PhD
Harvard Medical School
TOPIC: Targeting Notch in Cancer: Challenges and Opportunities

Stephen Elledge, PhD
Harvard Medical School
TOPIC: Genetic Approaches to Cancer

Michele Pagano, MD, PhD
New York University School of Medicine
TOPIC: Ubiquitin Ligases Regulate Modular Elements of Molecular Machines

2012


David E. Fisher, MD, PhD
Harvard Medical School
TOPIC: Signaling Pathways in Melanocytes and Melanoma Development

Martine F. Roussel, PhD
Member, St. Jude Children's Research Hospital Faculty
TOPIC: Molecular Networks and Cell of Origin of Pediatric Medulloblastoma

Charles J. Sherr, MD, PhD
St. Jude Children's Research Hospital
TOPIC: The INK4-ARF Tumor Suppressor: Regulation of Cellular Self-Renewal

2011


Judith Campisi, PhD
Lawrence Berkeley National Laboratory
TOPIC: Cancer and Aging: Rival Demons?

Ross Levine, MD
Memorial Sloan-Kettering Cancer Center
TOPIC: Role of Mutations in Epigenetic Modifiers in Myeloid Malignancies

John H. J. Petrini, PhD
Memorial Sloan-Kettering Cancer Center
TOPIC: Genetic Analysis of Chromosome Break Metabolism

Previous Invited Pelotonia Fellows

2016


Yannis Hadjiyannis
TOPIC: The coordination of E2F in HCC and beyond

Alicia Bao
TOPIC: Defects in tRNA intron turnover create novel small RNAs: possible consequences to cell growth

William Hankey
TOPIC: Chromatin-associated APC tumor suppressor protein antagonizes canonical WNT repression of the MALL gene

Brian Hurwitz
TOPIC: Oncolytic HSV-1 and proteasome inhibition synergistically treat solid tumors

Marie Lamantia
TOPIC: Argentine Tango Practice as a Balance Intervention for Cancer Survivors

Joseph Marquardt
TOPIC: Modular elements of the TPR domain in the Mps1 N terminus differentially target Mps1 to the centrosome and kinetochore

Nivedita Ratnam
TOPIC: NF--B Regulates Suppression Of Macrophage Activity During Early Tumor Development

Dinesh Ahirwar, PhD 
TOPIC: Fibroblast-Derived CXCL12 Promotes Breast Cancer Metastasis by Enhancing Tumor Vasculature Permeability

Chunming Cheng, PhD 
TOPIC: Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth

Hai Wang, PhD
TOPIC: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents

2015


Paula Agudelo-Garcia
TOPIC
: The Role of HAT1 in Protein Acetylation and Mitochondrial Function

Will Cantara, PhD
TOPIC
: Structural Characterization of Retroviral Genomes

Andrea Holderbaum
TOPIC
: Cooperation of NRASQ61R and ultra-violet light in the etiology of malignant melanoma

Chris Lucas, PhD
TOPIC
: Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug Resistance Mechanisms in a Leukemia Model

Sophia Maharry
TOPIC
: Dissection of the major hematopoietic quantitative trait locus in chromosome 6q23.3 identifies miR-3662 as a novel player in hematopoiesis

Brian Maxwell, PhD
TOPIC
: Investigation of the pathway regulated by E4 ubiquitin chain elongation and its role in VCP-mediated neurodegenerative disorders

Dongju Park
TOPIC
: Ablation of the BRCA1-PALB2 interaction phenocopies Fanconi Anemia

Steven Scoville
TOPIC
: Identification of a common human innate lymphoid cell progenitor in secondary lymphoid tissues

Gina Sizemore, PhD
TOPIC
: PDGFRβ signaling in the tumor microenvironment of metastatic breast cancer

Amit Srivastava, PhD
TOPIC
: Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells

Yihua Zhu
TOPIC: Novel roles of an Unc-13/Munc13 family protein in fission yeast cytokinesis 

2014


Adrienne Dorrance, PhD
TOPIC: Targeting Leukemia Stem Cells with AntagomiR-126 Nanoparticles in Acute Myeloid Leukemia

Markus Harrigan
TOPIC: A Genome-wide RNAi Screen for Novel Stromal-derived Oncogenic Signals in the Tumor Microenvironment

Samantha King
TOPIC: Soy Isoflavones and Metabolites as Immunomodulators for Cancer

Ta-Ming Liu, PhD 
TOPIC: Administration of Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: The Pre-Clinical Development of OSU-T315

Jason Pitaressi 
TOPIC: Genetic Ablation of Smoothened in Tumor Associated Fibroblasts Promotes Pancreatic Cancer Initiation

Mark Rudolph 
TOPIC: Combined Targeting of EGFR and Hedgehog Signaliing Pathway to Overcome Endocrine Resistance

Lawrence Shirley, MD 
TOPIC: Integrin-Linked Kinase Overexpression in the Dysregulated Stroma of Pancreatic Cancer and the Impact on Patient Survival

Andrew Stiff 
TOPIC: HDACi Increase the Anti-Myeloma Activity of Reolysin Through the Up-Regulation of the Reovirus Receptor JAM-1

Ramon Sun, PhD
TOPIC: Glutamine Metabolism is Required for Cell Proliferation in Hypoxia and Growth of Model Tumors

Jingyan Wu
TOPIC: Genome-Wide Screen Identifies Pathways That Govern tRNA Splicing and Intron Turnover in Saccharomyces Cerevisiae 

2013


Dinesh Ahirwar, PhD
TOPIC: Recombinant Slit2 protein inhibits breast cancer growth by inhibiting macrophages

Kyle Beckwith
TOPIC: A novel mouse model of human CD37-positive leukemia highlights the therapeutic potential of IMGN529

Ed Briercheck, PhD
TOPIC: Maximum natural killer cell cytolytic activity  requires optimum PTEN expression

Cai Chen
TOPIC: Transcriptome-wide RNA editing can be used in cancer subtype discrimination

Aishwarya Jacob
TOPIC: MDM2-ALT1: dual role as a suppressor and a driver of oncogenesis

Ben Hemmelgarn
TOPIC: Dissecting the Intersection Between the Rb/E2F and Myc Pathways in vivo

Nikola Kovinich, PhD
TOPIC: New Frontiers in the Chemical Arsenal Against Cancer: Combining Modules of Semi-Synthesis and Synthetic Biology

I-Ju Lee
TOPIC: Regulation of SPB assembly and cytokinesis by the centrin-binding protein Sfi1 in fission yeast

Kinshuk Mitra
TOPIC: Towards a more perfect separation: Leveraging microfluidics for marker capture and characterization

Ryan Reyes
TOPIC: miR-23a: A Key Metabolic Regulator in Hepatocellular Carcinoma

Rachel Zielinski
TOPIC: Targeting Cellular Biomechanics to Modulate Cancer Cell Motility and Tumor Morphogenesis

2012


Christina Austin
TOPIC: Essential Roles and Functional Redundancy of EGFR Ligands in Drosophila Development

Kyle Beckwith
TOPIC: Human CD37 mouse models for evaluation of targeted therapeutics for B cell malignancies

Hemant Bid, PhD
TOPIC: Targeting the IGF-axis as a strategy to suppress tumor angiogenesis

Ann Kathrin Eisfeld, MD
TOPIC: miR-3151 interplays with its host gene BAALC and independently impacts on outcome of patients with cytogenetically normal acute myeloid leukemia

Nancy Engelmann Moran, PhD
TOPIC: Development of a 13C-enriched lycopene for human metabolic studies and assessment of anti-cancer mechanisms of action

Patrick Grierson
TOPIC: The BLM helicase senses nucleolar stress as a component of an RNA polymerase I-associated complex

Daniel Kiss, PhD
TOPIC: Cytoplasmic mRNA Recapping, P-Bodies, and Capping Inhibited mRNAs

George Koutras
TOPIC: Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: A strategy to re-introduce fenretinide for oral cancer chemoprevention

Huayang Liu
TOPIC: A Genome-wide RNAi Screen to Identify Novel Regulators of the Tumor Microenvironment

James Phelan
TOPIC: Growth factor independence 1 (Gfi1) antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia

Kathryn Takamura
TOPIC: Dextran Vesicles: A Versatile Renewable Drug Carrier for Camptothecin Loading and Delivery into Cells

Salene Wu
TOPIC: Anxiety, Worry, and Inflammation in Women with Recurrent Cancer

2011


Enrico Caserta, PhD
TOPIC: Tumor Suppression Functions of PTEN in Stromal Cells

Hsiao-Ching Chuang
TOPIC: Combining poly-(ADP-ribose) polymerase (PARP) inhibitors with Energy Restriction-Mimetic Agents (ERMAs) as a novel therapeutic approach for triple-negative breast cancer

Nripesh Dhungel
TOPIC: tRNA splicing endonuclease: Investigating novel functions

Jonathan Lee
TOPIC: A Genome-Wide Screening of Drosophila melanogaster to Identify Endoreduplication Specific Genes

Dustin Gable
TOPIC: Ets1 as a Potential Target of MicroRNA-1 in Cutaneous Squamous Cell Carcinoma

April Gocha
TOPIC: BRCA1 Interactions with RecQ-like Helicases in the Control of Telomere Maintenance

Kevin Kauffman
TOPIC: Pulmonary Polymeric Microparticles for the Treatment of Lung Cancer

Jiang Li, PhD
TOPIC: Molecular Mechanism of DNA Repair by (6–4) Photolyase

Parvathi Ranganathan, PhD
TOPIC: Regulation of Acute Graft-Versus-Host Disease by microRNA-155

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication